Detalles de la búsqueda
1.
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
BMC Cancer
; 23(1): 72, 2023 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36670414
2.
Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma.
Cancer Control
; 30: 10732748221148912, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36592162
3.
Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
Cancer Immunol Immunother
; 71(5): 1247-1255, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34647153
4.
Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
Cancer Immunol Immunother
; 71(3): 637-644, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297160
5.
The perception gap of chemotherapy-induced adverse events between doctors and cancer patients: an observational study in China.
Support Care Cancer
; 29(3): 1543-1548, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32728801
6.
KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer.
Oncologist
; 25(8): 650-e1145, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32134163
7.
Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
Mol Cancer
; 18(1): 7, 2019 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30626401
8.
Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
Int J Cancer
; 144(11): 2854-2866, 2019 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30430561
9.
A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
Oncologist
; 24(7): 891-e431, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31048330
10.
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
BMC Cancer
; 19(1): 595, 2019 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31208370
11.
Cause-specific death assessment of patients with stage I small-cell lung cancer: a competing risk analysis.
Future Oncol
; 15(21): 2479-2488, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31238738
12.
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Lancet Oncol
; 19(10): 1338-1350, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30213452
13.
Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: A pan-cancer analysis of the SEER database.
Int J Cancer
; 143(7): 1569-1577, 2018 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29667174
14.
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
Oncologist
; 23(5): 603-616, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29330211
15.
Retraction Note: p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells.
BMC Cancer
; 23(1): 386, 2023 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37122006
16.
p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells.
BMC Cancer
; 18(1): 641, 2018 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29879950
17.
Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis.
Future Oncol
; 14(19): 1933-1941, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30019968
18.
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 388(10054): 1883-1892, 2016 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27567279
19.
Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus.
Cancer Immunol Immunother
; 71(5): 1257, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34870721
20.
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Cancer Immunol Immunother
; 66(9): 1175-1187, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28451792